Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schi ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Neurocrine Biosciences (NBIX) , which belongs to the Zacks Medical - Drugs industry, could be a great candidate to consider.This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 18.64%.For the most recent quarter, Neuro ...

Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026. The schedule for the press release and conference call / webcast is as follows: Q4 and Year-End 2025 Press Release: February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ET ...

These data are consistent with our integrated understanding of the TO of INGREZZA and drug exposure concentrations observed from INGREZZA in pivotal clinical trials. The superior target engagement observed with INGREZZA may be related to its single high affinity metabolite, compared with AUSTEDO XR, which generates multiple metabolites, including those with lower VMAT2 affinity. SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first ...

Core Themes - Neurocrine emphasizes two overarching themes for 2026: strong and building momentum, and strategic balanced diversification [3]. Momentum - The company aims to highlight its momentum, drawing parallels to the physics definition of momentum, indicating a focus on growth and progress [4]. Strategic Diversification - Neurocrine is committed to a strategy of balanced diversification, which is expected to play a crucial role in its future development and stability [3].

Neurocrine Biosciences FY Conference Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **Key Speaker**: Kyle Gano, CEO Core Themes 1. **Strong and Building Momentum** - Neurocrine has a workforce of 2,000 and a proven track record in discovering, developing, and commercializing medicines for patients [2][3] - The company has four FDA-approved medicines, including Ingrezza and Crinecerfont, which are marketed in the U.S. [3] - In 2025, Ingrezza is projected to generate $2.5-$2.55 billion in net sales, while Crinecerfont achieved $166 million in net sales in its first nine months [4] 2. **Strategic Balanced Diversification** - Transitioned from a single product company focused on small molecules to a diversified biopharmaceutical company [5][6] - Crinecerfont is expected to be a significant contributor to revenue diversification alongside Ingrezza [6] - The company is expanding its R&D efforts into new therapeutic areas, including peptides, antibodies, and gene therapies [7][8] Financial Performance - **Ingrezza**: Projected net sales of $2.5-$2.55 billion for 2025 [4] - **Crinecerfont**: $166 million in net sales for the first nine months of commercialization [4] R&D Pipeline - **Current Pipeline**: 12 programs in clinical development (8 in phase one, 2 in phase two, 2 in phase three) [35] - **Goals**: Targeting four new phase one programs and advancing two new phase two programs annually [11] - **Focus Areas**: Neurology, psychiatry, endocrinology, with a strong emphasis on validated biology [35] Key Products and Programs 1. **Crinecerfont**: - First approved treatment for classic congenital adrenal hyperplasia (CAH) [41] - Positive two-year data showing robust efficacy and safety, with an 80% retention rate in the open-label extension study [24][45] - 40% of patients experienced a 5% or greater weight loss during the two-year period [25] 2. **Neuropsychiatry Portfolio**: - Includes first-in-class AMPA PAM for major depressive disorder and Derecladine for schizophrenia [13][14] - Both programs are in phase three trials, with potential to change the standard of care [37] 3. **Emerging Endocrinology Pipeline**: - Focused on CRF biology, with programs targeting obesity and metabolic disorders [17][19] - New molecule MBIP2118 for obesity is set to be a once-weekly injectable with a differentiated product profile [19] Market Strategy - **Sales Force Expansion**: Aiming to deepen engagement with endocrinologists and reach patients not currently under specialized care [48] - **Reimbursement Success**: Patients have been able to secure commercial reimbursement within a week, exceeding initial expectations [43] Safety and Efficacy - Crinecerfont has shown a favorable safety profile with no new safety warnings and a low rate of adrenal insufficiency [49][50] - Long-term steroid reduction has led to improvements in weight loss and insulin resistance, critical for patients with CAH [50] Future Outlook - Anticipated data flow from various programs, including gene therapy for Friedreich's Ataxia and weight loss data from CRF2 peptide studies [38] - Continued focus on building a robust R&D engine to support future growth and innovation [36] Conclusion - Neurocrine is positioned for significant growth in 2026 and beyond, with a strong pipeline and strategic diversification efforts aimed at enhancing patient care and expanding market reach [9][10]

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

thSAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44 Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. The live presentation will be webcast and can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour aft ...

Core Viewpoint - Deutsche Bank reiterated its "Hold" rating on Neurocrine Biosciences (NBIX.US) and maintained a target price of $152, believing that investor expectations for the clinical results were low, thus the impact on the stock price will be minimal [1] Group 1: Clinical Trial Results - Neurocrine Biosciences reported that the Phase III KINECT-DCP trial for valbenazine (Ingrezza) in treating Dystonic Cerebral Palsy (DCP) failed, eliminating the opportunity for Ingrezza to expand its indications beyond tardive dyskinesia (TD) and Huntington's disease (HD) [1] - The failure of the DCP indication for Ingrezza was not included in Deutsche Bank's valuation model, meaning it will not alter the company's valuation [1] Group 2: Sales Estimates and Market Focus - Deutsche Bank estimates the peak sales for Ingrezza to be approximately $2.821 billion, compared to consensus expectations of about $2.998 billion, which includes around $2.585 billion from TD sales and approximately $236 million from HD sales [2] - In the absence of label expansion, Deutsche Bank expects management to focus on increasing Ingrezza prescriptions, supported by an expanded sales team, while the TD market is anticipated to grow despite currently low penetration [2]

Neurocrine Biosciences Inc. (NASDAQ:NBIX) on Monday shared data from its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP).Cerebral palsy (CP) is a nonprogressive neurodevelopmental disorder that affects movement and posture, starting in early childhood. It occurs in about three per 1,000 children in the United States.People living with dyskinetic cerebral palsy (DCP) often have mixed hyperki ...